Dextromethorphan, Gabapentin, and Oxycodone to Treat Opioid-Induced Hyperalgesia

• Status: Completed
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Individuals who reduce or stop use of opioid medications are at risk for developing hyperalgesia, which is an increased sensitivity to pain. This study will compare the effectiveness of dextromethorphan, gabapentin, and oxycodone at reducing hyperalgesia in individuals addicted to opioids who are concurrently receiving methadone treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute on Drug Abuse (NIDA)
• Treatments: Gabapentin; gamma-Aminobutyric Acid

Criteria

Inclusion Criteria:

• Be between the ages of 18 and 55 years of age.

• Meets DSM-IV diagnostic criteria for opioid dependence

• Taking a stable dose of methadone for 6 weeks prior to study entry and is compliant in methadone maintenance treatment

• Is in good physical health or under a physician's care if a medical condition requires ongoing treatment

Exclusion Criteria:

• Known sensitivity to dextromethorphan, gabapentin, or oxycodone

• Currently dependent on alcohol, benzodiazepine, or any drug (other than nicotine)

• Currently in an acutely psychotic, severely depressed state and in need of inpatient treatment

• Immediate suicide risk

• Neurological or psychiatric illness (e.g., peripheral neuropathy, schizophrenia, neuropathic pain, Raynaud's disease, or urticaria)

• Acute medical condition that would make study participation medically dangerous (e.g., acute hepatitis, unstable cardiovascular disease, liver disease, or kidney disease)

• Liver enzyme values five times greater than normal

• Currently taking analgesic medication for a painful condition on a regular basis

• Current or past history of high blood pressure, heart disease, or stroke

• Currently using a pacemaker

• Pregnant or breastfeeding